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1. Introduction 
Factor IX is the coagulation factor which is absent 
or present in an inactive form in individuals with 
hemophilia B. It was recently obtained in pure form 
[ 1,2] and shown to be a single-chain glycoprotein of 
mol. wt. 72 000. Factor IX, together with Factors II, 
VII and X require vitamin K for the biosynthesis of 
active factor. 
Studies on the biosynthesis of bovine prothrombin 
(Factor II) have shown that in the absence of vitamin 
K a protein is made that in most respects is identical 
to prothrombin but devoid of coagulant activity [3]. 
This deficiency can be related to the absence of the 
special calcium ion binding properties that are 
characteristic for normal prothrombin. Recently it 
was shown [4,5] that normal prothrombin contains 
a number of residues of an unusual amino acid, 
y-carboxyl glutamic acid. These residues are located 
in the amino-terminal portion of the prothrombin 
molecule and are involved in the binding of calcium 
and probably phospholipid (platelet factor 3). They 
are probably formed by a vitamin K dependent 
carboxylation reaction of certain glutamic acid 
residues in the newly synthesized protein. The 
prothrombin-like molecule synthesized in the 
absence of vitamin K does not contain this amino acid. 
It is probable that the other vitamin K dependent 
coagulation factors also contain y-carboxyl glutamic 
acid residues but it has not been proved yet. 
In this study the ammo acid sequence of the 
N-terminal fourteen residues of human Factor IX, 
has been determined. y-Carboxyl glutamic acid 
residues are found at positions 7 and 8. Considerable 
North-Holland Publishing Company - Amsterdam 
homology with bovine Factor IX and bovine 
prothrombin is seen. 
2. Materials and methods 
2.1. Isolation of Factor IX 
Factor IX was isolated from fresh frozen human 
plasma by ion-exchange chromatography on DEAE 
Sephadex, affinity chromatography on heparin- 
agarose gel and gel filtration on Sephadex G-200 as 
described by Andersson et al. [ 1 ] . An additional gel 
filtration on Sephadex G-200 was introduced in 
order to remove aggregated and degraded and Factor IX 
The protein was shown to be homogeneous by 
immunoelectrophoresis, polyacrylamide and gradipore 
polyacrylamide electrophoresis. 
2.2. Edman degradation 
All reagents used were of Pierce Sequenal grade. 
Sequence analysis was performed by the manual 
Edman procedure as described earlier by Fryklund 
et al. [6]. Phenylthiohydantoin (PTH) amino acids 
were identified by thin-layer chromatography or 
paper electrophoresis [6] with the modification thar 
10 X 10 cm silica gel plates were used instead for 
chromatography to increase sensitivity and decrease 
running time. 
2.3. Synthesis and identification of PTH y-carboxyl 
glu tamic acid 
y-Carboxyl glutamic acid (monoammonium salt) 
was a very kind gift from Dr Johan Stenflo. The PTH 
derivative was synthesized from 1 mg essentially as 
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described by Edman [7] and characterized by thin- 
layer chromatography and paper electrophoresis. 
3. Results and discussion 
Fourteen cycles of Edman degradation were 
performed on 35 nmol of Factor IX. At both stages 
7 and 8 the PTH amino acids observed on thin layer 
suggested Glu and two other components migrating 
approximately as Gln and Asp. Paper electrophoresis 
of stages 7 and 8 gave the pattern shown in fig.1, 
where the samples show both PTH-Glu and the faster 
moving anodic spot characteristic of the PTH 
derivative of y-carboxyl glutamic acid which is 
carrying an additional negative charge. Fernlund et al. 
[4] find that the PTH derivative of y-carboxyl glutamic 
acid is labile during degradation. In the degradation 
conditions used by us (viz., coupling with phenyl- 
isothiocyanate at pH 9.5 for 1 h at 4O”C, cyclization 
with trifluoracetic acid at 40°C for 20 min, and 
conversion at 80°C in 1 N HCl) we also observe some 
decarboxylation to PTH-Glu and the formation of the 
other unidentified components observed on thin-layer 
chromatography. In stages 7 and 8 approx. equal 
amounts of the two anodic spots (fig.1) are present, 
whereas in the PTH r-Glu standard, the greater 
proportion is in the form of the faster anodic spot. 
The direct PTH technique and the use of paper 
electrophoresis thus allow identification of y-carboxyl 
glutamic acid at positions 7 and 8 without using mass 
spectrometry. 
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Fig.1. Diagrammatic representation of the results obtained by 
paper electrophoresis performed at pH 6.5 in sodium phos- 
phate buffer containing starch for 2 h at 400 V [6]. The 
PTH derivatives were detected as white spots on a coffee 
coloured background by means of the iodine azide reagent [ 7 1. 
Fig.2 shows the complete sequence obtained up to 
residue 14, and a comparison with bovine Factor IX 
described by Fujikawa et al. [8] shows differences at 
residues 3 and 6. A comparison with bovine 
prothrombin [5] shows that there is considerable 
homology, and that the position of the two y-carboxyl 
glutamic acid residues are the same. Residues 2,4, 12, 
13, and 14 are also identical in all three molecules. 
The Factor IX used in this study has been prepared 
by a combination of DEAE-Sephadex chromatography, 
affinity chromatography on heparin-Sepharose and 
Sephadex G-200 gel filtration [l] . However, there is 
also another published procedure for obtaining pure 
Factor IX 121 involving a number of steps including 
6 7 a 9 IO II 12 13 14 15 
Human Factor 1X Tyr-Asn-lle-Gly-Lys-Asn-Gla-G[a-Phe-Val-Arg-Gly-Asn-Leu 
XI XI 
Bovine Factor IX 
(Fujikawa et al.) 
Tyr-Asn-Ser-Gly-Lys-Leu-Glx-Glx-Phe-Val-Arg-Gly-Asn-Leu-Cys- 
Bovine Prothrombin 
(Magnusson et al. ) 
Ala-Asn-Lys-Gly-Phe-Leu-Gla-Gla-Val-Arg-Lys-Gly-Asn-Leu 
x) xl 
Xl y-carboxyl glutamic acid 
Fig.2. Amino terminal sequence comparison between human and bovine Factor IX and bovine prothrombin. 
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barium sulphate adsorption and preparative poly- 
acrylamide gel electrophoresis. 
The two methods result in Factor IX preparations 
that are similar in many respects including molecular 
weight. There is one important difference however 
in the aminoterminal residue, being tyrosine in the 
preparation of Andersson et al. [l] and glycine in the 
preparation of asterud and Flengsrud [2]. The results 
obtained in this study show that the ‘tyrosine-Factor 
Ix’ has an N-terminal sequence that is homologous 
to that of bovine Factor IX and prothrombin. This 
strongly indicates that the ‘tyrosine-Factor 1X’.is the 
native form of the factor. The ‘glycine-Factor IX’ is 
probably a partly activated or degraded form. The 
presence of aminoterminal glycine suggests that 
proteolytic cleavage could have occurred between 
residues 11 and 12 at the Arg-Gly bond. This bond 
is likely to be sensitive to thrombin-catalyzed 
hydrolysis. Furthermore, the sequence 
$e-%--Alrk is identical to that in a commonly used 
peptide substrate (S-21 60) for thrombin determina- 
tion [9]. Trace amounts of thrombin are easily formed 
during the purification of Factor IX since prothrombin 
is usually present in large amounts at least in the 
initial steps. 
In conclusion, human Factor IX has, as the first 
human protein, been shown to contain y-carboxyl 
glutamic acid residues. The N-terminal sequence is 
homologous to that of prothrombin indicating 
similarities in the mechanism of binding to calcium 
and phospholipid (platelet factor 3) and the existence 
of a common precursor. 
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